Iowa Approach

We have a faster, safer, and more cost-effective way to perform catheter-based atrial fibrillation ablation without entering the left atrium

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Iowa City, IA, USA
  • Currency USD
  • Founded January 2012
  • Employees 4
  • Website

Company Summary

Iowa Approach, Inc. is developing proprietary medical devices for treating one of the world’s most common heart rhythm disorders, atrial fibrillation (AF), a condition that affects an estimated 67 million people worldwide. Our innovative technology and new clinical procedure to percutaneously treat AF appears to be dramatically faster, potentially safer, and significantly more cost effective than current treatment approaches.


  • Allan Zingeler
    CEO & Director

    Allan Zingeler, BS, brings nearly 30 years of business management, medical device commercialization, and President/CEO-level experience in the medical device Afib industry. Allan has a successful track record of creating value for shareholders and helped lead a prior catheter device company that pioneered the cryo-balloon (CryoCath) in the Afib space from start-up to $40M in annual sales and $400M (10x sales) acquisition by Medtronic.

  • Steven Mickelsen
    Founderl/CTO; Director

    Steven Mickelsen, MD, is the founder and CMO and brings over 15 years of research experience in heart rhythms and an in-depth understanding of this highly specialized field. Dr. Mickelsen was a Howard Hughes Research Scholar at the National Heart, Lung, and Blood Institute (NHLBI) from 2004-2005, trained in Internal Medicine at Mayo Clinic from 2007-2010, and is now at University of Iowa Hospitals and Clinics as an Electrophysiology Fellow.

  • Gary Long
    VP R&D

    Gary Long, BS, PhD, is an electrical engineer and VP R&D who has worked in early product research and development for the past 32 years and spent the last 24 years on medical device development both on the start-up side and for J&J. Gary has 60+ patents, and more importantly, valuable insight into what truly defines minimal invasive procedures as well as effective research and development strategies and tactics in the medical device arena.

  • Dr. Howard Dittrich
    Chairman of the Board

    Howard C Dittrich, MD, FACC is serving on the Board of Directors and has been involved as Chief Medical Officer (CMO) of multiple life science companies from start-up to acquisitions ranging $350-560 million. This includes NovaCardia, acquired in 2007 by Merck & Co., Corthera, acquired in 2009 by Novartis, and TargeGen, acquired in 2010 by Sanofi Aventis. Dr. Dittrich brings extensive experience and a network of investors & strategic partners.

  • John Slump

    John Slump, BBA, is serving on the Board of Directors for Iowa Approach and brings medical device start-up experience and CFO-level expertise as well as a finance/accounting educational background. Most recently as Founder/CFO of Corvida Medical, Mr. Slump has led fundraising efforts, securing about $10M in start-up capital - with 1/3 NIH grants and other non-dilutive funds, capitalizing the company to FDA approval & initial commercialization.


  • Greg Williams & Tom DeBoom - Simmon Perrine Law Firm
    McGladery CPA Firm
    Kalyanam Shivkumar, M.D., Ph.D.
    Director, UCLA Cardiac Arrhythmia Center & EP Programs & Iowa Approach Scientific Advisory Board Member
  • Fred Kusumoto, M.D., FACC
    Professor of Medicine, Mayo Clinic; Iowa Approach Scientific Advisory Board Member
    Andrea Natale, MD, FACC, FHRS
    Executive Medical Director, Texas Cardiac Arrythmia Institute, St. David's Medical Center; Consulting Professor, Division of Cardiology, Stanford University

Previous Investors

  • Wellmark Blue Cross Blue Shield of Iowa
    Iowa Economic Development Authority
    Angel Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free